Abeona Therapeutics Inc. — Q1 2023 Form 10-Q
Business context and period: Clinical-stage biopharmaceutical company developing cell and gene therapies. This unaudited report covers the three months ended March 31, 2023; comparative figures are for Q1 2022 unless otherwise noted. Amounts below are in U.S. dollars.
Financial performance and position
| Metric | Q1 2023 / March 31, 2023 | Q1 2022 / December 31, 2022 |
|---|---|---|
| Revenue | $0 | $346,000 |
| Research and development expense | $8.0 million | $10.5 million |
| General and administrative expense | $4.0 million | $4.2 million |
| Net loss | $9.1 million | $22.0 million |
| Basic and diluted loss per share | $0.54 | $3.80 |
| Cash used in operating activities | $11.7 million | $13.7 million |
| Cash, cash equivalents, restricted cash and short-term investments | $40.7 million | $52.5 million |
| Total assets | $53.3 million | $64.2 million |
| Total liabilities | $34.6 million | $37.5 million |
| Stockholders’ equity | $18.7 million | $26.8 million |
The company reported no product revenue and remains unprofitable; profit margins are not meaningful. Operating expenses totaled $12.0 million. At quarter-end, cash and cash equivalents were $4.7 million, restricted cash $0.3 million, and short-term investments $35.7 million. The filing reports no conventional borrowing balance; liabilities include $7.3 million of operating lease liabilities, a $4.3 million payable to licensor, and $17.4 million of warrant liabilities.
Material changes and notable items
- Net loss narrowed by $12.9 million year over year. Lower R&D spending and the absence of $6.2 million in impairment charges recorded in Q1 2022 were major factors; Q1 2022 revenue of $346,000 did not recur.
- R&D expense declined $2.5 million, primarily due to reduced work on ABO-101 and ABO-102, which were discontinued or transferred to a partner. G&A expense declined $0.2 million.
- A $2.3 million noncash gain from the change in fair value of warrant liabilities benefited Q1 2023 results; Q1 2022 included a $1.3 million loss. Interest income increased to $364,000 from $7,000, mainly reflecting higher rates and investment balances.
- Operating cash use decreased by $1.9 million year over year. Investing activities provided $2.2 million, mainly from net maturities of short-term investments; financing activities used $4,000.
- The company corrected a prior-period warrant-accounting error in the Q1 2022 comparative figures: the restated net loss was $22.0 million, versus $20.8 million as originally reported. The correction did not change reported operating cash flow.
Outlook, risks and contingencies
- Management planned to submit an FDA Biologics License Application for EB-101 in late Q2 or early Q3 2023, based on positive topline results from the VIITAL study. The filing described statistically significant improvements in wound healing and pain reduction; it also reported further analyses presented in May 2023.
- The company said existing cash resources were expected to fund operations for at least 12 months from the report date, but additional financing may be needed to complete planned development and commercialization activities. It expects continued losses and substantial R&D spending and gave no assurance of achieving profitability.
- Key risks include BLA submission and regulatory outcomes, manufacturing readiness and supply, access to additional capital, potential shareholder dilution, clinical and development uncertainty, and dependence on partners and vendors. The company’s ATM agreement permits sales up to $150 million in aggregate, subject to Form S-3 public-float limits; it sold 98,560 shares during Q1 and reported approximately $0.3 million of net proceeds receivable.
- Ultragenyx holds worldwide rights to develop, manufacture and commercialize ABO-102. Abeona may receive tiered royalties and up to $30 million in commercial milestones following approval, but these amounts were not recognized as revenue in Q1.
- The company reported no legal proceedings and no material changes to previously disclosed risk factors. Management concluded disclosure controls were effective as of March 31, 2023.
Important facts for investors to verify
- Whether and when Abeona submitted the EB-101 BLA, and the FDA’s response and review timeline.
- Current unrestricted cash, investment balances, quarterly cash burn, and the assumptions supporting the stated 12-month runway.
- Funding needs and available ATM capacity, including the impact of the Form S-3 issuance limit and potential dilution.
- EB-101 commercial manufacturing readiness, regulatory compliance, and the ability to secure a commercialization partner.
- The status of the ABO-102 license arrangement and any future reimbursement, milestone, or royalty receipts.
- Warrant liability valuation and potential dilution: approximately 9.4 million warrants were outstanding at quarter-end, subject to their exercise terms.